Executive Vice Chair, Department of Diagnostic, Molecular, and Interventional Radiology Mount Sinai Health System

Joined April 2013
719 Photos and videos
I ask my professional contacts and colleagues to follow this model. Please block all anonymous accounts. The tone of these accounts has become increasing aggressive and harmful. They do not deserve your attention. If you follow, you are endorsing this behavior on #medtwitter
We have chosen to block all anonymous accounts as they do not represent our views. We recommend that our followers block them as well. Please do not ask us to respond to any content from anonymous accounts as they are not on our feed and not worthy of our (and your) attention.
9
8
114
Live @SIRspecialists Publication Alert!!! The 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: Pertinent Points for the Interventional Radiologist jvir.org/article/S1051-0443%…
2
9
618
Robert A Lookstein MD, MHCDL retweeted
What does it really take to run a high-volume Y-90 program that is efficient, scalable, and patient-centered? In this episode of BackTable 2026 HCC Creator Weekend™, host Dr. Zach Berman is joined by Drs. Nima Kokabi and @kiremagarciamd to break down the systems, workflows, and strategies that drive successful radioembolization centers. 🎧Tune into the full episode on the BackTable App: na2.hubs.ly/H05VKjq0 This podcast is supported by an educational grant from Sirtex and Boston Scientific. #VI651 #InterventionalRadiology #IRad #VIR #HepatocellularCarcinoma #HCC #Y90 #Radioembolization #MedEd #BackTable @UNC_Health_Care @MountSinaiNYC
1
14
664
Live #GEST2026 always great to get an impromptu strategic catch up between @SIRspecialists #Prez @saherssabri and yours truly as immediate #PastPrez
1
28
978
Robert A Lookstein MD, MHCDL retweeted
Examining the applications of embolization, a group from @IcahnMountSinai details how excellence can be achieved across diverse applications, underscoring the importance of technique refinement, cross-specialty collaboration, & procedural standardization. evtoday.com/articles/2026-ap…
1
2
6
806
Live @MountSinaiIR #GEST2026 #MeettheExperts with no other than @bonesz sharing tips for tackling complex #PAE cases @SIRspecialists
1
16
1,071
Live @MountSinaiIR our very own @RSP516 wins abstract of the year at #GEST2026 for his work as National PI for the OCCLUDE registry. 🙌👏
6
42
1,665
#SIRTOR26 incredible memories...proud to serve @SIRspecialists and appreciate what we have accomplished as a team of dedicated volunteers and inspiring professional staff. Already looking forward to #SIRLA27
22
562
Live @MountSinaiIR innovation is what distinguishes our group, providing creative solutions for our patients. @DanShilo is leading our #MSK embolization program @MountSinaiNYC mountsinai.org/about/patient…
2
16
1,429
Live @MountSinaiIR we are proud to share we performed 56 outpt embolizations for UFE,PAE,GAE, and HAE at our Embolization Center of Excellence @MountSinaiNYC WestCampus in April. This is a testament to our MDs, nurses, technologists, office staff, and our patients. TYSM!!
3
3
29
2,680
Live @CXSymposium at the end of the Pulm Embolism morning session and review of all the new trial data, the audience clearly believes reperfusion therapy will continue to grow over the next several months/years. @SIRspecialists @SCAI @VascularSVS @SVM_tweets @VIVAPhysicians
2
5
504
Live @CXSymposium more discussion on the New Pulm Embolism Guidelines from @RKolluriMD
1
12
697
Live #CX2026 The Pulmonary Embolism Consensus Session is underway with @adityasharmamd
1
1
2
570
Robert A Lookstein MD, MHCDL retweeted
Apr 20
STORM-PE: Mechanical Thrombectomy Boosts Walking and Daily Living Gains dlvr.it/TS7Srl
1
2
515
Robert A Lookstein MD, MHCDL retweeted
STORM-PE 90-day results demonstrates greater improvement in functional outcomes using #CAVT compared to patients who received anticoagulation alone, reports @roblookstein, adding that CAVT patients walked "significantly farther" at follow-up #SIR26TOR @SIRspecialists
1
5
439
Robert A Lookstein MD, MHCDL retweeted
#SIR26TOR: 12-month IN.PACT AV Access post-approval study results show a 70% rate of target-lesion primary patency and 80.6% freedom from all-cause mortality in 159 patients, with no new safety concerns reported when compared to IN.PACT AV randomised controlled trial
1
5
514